- Home
- PRPO vs RNTX Comparison
PRPO vs RNTX Comparison
Compare PRPO & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRPO
- RNTX
- Stock Information
- Founded
- PRPO N/A
- RNTX 2001
- Country
- PRPO United States
- RNTX United States
- Employees
- PRPO N/A
- RNTX N/A
- Industry
- PRPO Biotechnology: Laboratory Analytical Instruments
- RNTX Biotechnology: Pharmaceutical Preparations
- Sector
- PRPO Industrials
- RNTX Health Care
- Exchange
- PRPO Nasdaq
- RNTX Nasdaq
- Market Cap
- PRPO 30.2M
- RNTX 34.6M
- IPO Year
- PRPO N/A
- RNTX N/A
- Fundamental
- Price
- PRPO $20.66
- RNTX $1.58
- Analyst Decision
- PRPO
- RNTX Buy
- Analyst Count
- PRPO 0
- RNTX 2
- Target Price
- PRPO N/A
- RNTX $10.00
- AVG Volume (30 Days)
- PRPO 15.0K
- RNTX 156.7K
- Earning Date
- PRPO 11-06-2025
- RNTX 11-13-2025
- Dividend Yield
- PRPO N/A
- RNTX N/A
- EPS Growth
- PRPO N/A
- RNTX N/A
- EPS
- PRPO N/A
- RNTX N/A
- Revenue
- PRPO $21,242,000.00
- RNTX N/A
- Revenue This Year
- PRPO N/A
- RNTX N/A
- Revenue Next Year
- PRPO N/A
- RNTX N/A
- P/E Ratio
- PRPO N/A
- RNTX N/A
- Revenue Growth
- PRPO 27.05
- RNTX N/A
- 52 Week Low
- PRPO $3.90
- RNTX $1.04
- 52 Week High
- PRPO $22.38
- RNTX $4.40
- Technical
- Relative Strength Index (RSI)
- PRPO 57.34
- RNTX 63.81
- Support Level
- PRPO $16.40
- RNTX $1.30
- Resistance Level
- PRPO $21.67
- RNTX $1.52
- Average True Range (ATR)
- PRPO 1.46
- RNTX 0.11
- MACD
- PRPO 0.10
- RNTX 0.02
- Stochastic Oscillator
- PRPO 75.98
- RNTX 97.37
About PRPO Precipio Inc.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.
About RNTX Rein Therapeutics Inc. Common Stock
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.